High dose therapy for Hodgkin's disease.

Area of Science:

• Oncology
• Hematology

Background:

• High-dose therapy with hematopoietic stem cell support is standard for relapsed Hodgkin's disease (HD).
• Limited randomized trial data support this practice, especially for patients in first complete remission.

Purpose of the Study:

• To review the efficacy of high-dose salvage therapy for Hodgkin's disease.
• To discuss salvage strategies for patients relapsing after high-dose therapy.

Main Methods:

• Review of existing literature and clinical data on high-dose therapy for Hodgkin's disease.
• Analysis of progression-free survival rates and response to subsequent therapies.

Main Results:

• Approximately 40% of patients achieve prolonged progression-free survival with high-dose salvage therapy.
• Relapsed patients often show transient responses to conventional therapy post-high-dose treatment, unlike in non-Hodgkin's lymphoma.

Conclusions:

• High-dose therapy is effective for a subset of Hodgkin's disease patients, but further research is needed.
• Improved salvage strategies are necessary as front-line therapy advances select poorer prognosis patients for high-dose treatment.